RHAPSEDA

Group A Strep (GAS), kills >500,000 people and causes >700 million infections annually worldwide. GAS demonstrates a worrying increase in antibiotic resistance. There is no vaccine. This is now a WHO priority.

With our patented glycoconjugate vaccine production platform, RHAPSEDA will be the first to recombinantly produce universal multivalent GAS vaccine candidates. Compared to the traditional chemical approach for making glycoconjugate vaccine antigens, the RHAPSEDA platform employs a straight forward manufacturing process which has the potential to create a vaccine that will be affordable to Low-to-Middle Income Countries (LMICs).

The platform may also be applicable to other streptococcal subgroups.